Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2017, Article ID 3736201, 6 pages
Review Article

Safety of Human Papillomavirus 9-Valent Vaccine: A Meta-Analysis of Randomized Trials

1Postgraduate Program in Health Sciences, Federal University of Rio Grande do Norte, Natal, RN, Brazil
2Department of Gynecology and Obstetrics, University Potiguar (UnP), Natal, RN, Brazil
3Department of Gynecology and Obstetrics, Federal University of Rio Grande do Norte (UFRN), Natal, RN, Brazil
4Department of Gynecology and Obstetrics, State University of Campinas (UNICAMP), Campinas, SP, Brazil

Correspondence should be addressed to Ricardo Ney Oliveira Cobucci; moc.liamtoh@iccubocnr

Received 24 February 2017; Revised 9 May 2017; Accepted 4 June 2017; Published 24 July 2017

Academic Editor: Angelika Riemer

Copyright © 2017 Ana Paula Ferreira Costa et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Vaccination against human papillomavirus (HPV) has been progressively implemented in most developed countries for approximately 10 years. In order to increase the protection of the vaccines, a 9-valent vaccine (HPV9) was developed, which provides protection against nine types of the virus. Studies evaluating its safety are rare. Thus, we performed a meta-analysis of three clinical trials assessing adverse effects on women randomly vaccinated with HPV9 or tetravalent vaccine (HPV4), with the objective of analyzing whether the HPV9 is as safe as HPV4. An electronic data search was performed through the PubMed, Embase, Scopus, Web of Science, and SciELO databases. The studies selected 27,465 women who received one of the two vaccines. Pain (OR 1.72; 95% CI 1.62–1.82) and erythema (OR 1.29; 95% CI 1.21–1.36) occurred significantly more in the HPV9 group. However, there was no significant difference between the groups for the following adverse effects: headache (OR 1.07; 95% CI 0.99–1.15), dizziness (OR 1.09; 95% CI 0.93–1.27), and fatigue (OR 1.09; 95% CI 0.91–1.30), and the occurrence of serious events related to vaccination was similarly rare among those vaccinated. Therefore, our findings demonstrate that HPV9 in female patients is as safe as the tetravalent vaccine.